Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2011

01.07.2011 | Epidemiology

Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer

verfasst von: Rulla M. Tamimi, Graham A. Colditz, Yihong Wang, Laura C. Collins, Rong Hu, Bernard Rosner, Hanna Y. Irie, James L. Connolly, Stuart J. Schnitt

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The growth hormone and insulin-like growth factor (IGF) axis plays an essential role in the growth and development of the mammary gland. IGF1 and IGF1 receptor (IGF1R) may also play a role in the early transformation of mammary cells. Using a nested case–control design, the association between IGF1R expression in normal breast tissue from benign biopsies and subsequent risk of breast cancer was examined in patients enrolled in the Nurses’ Health Study. The tissue microarrays (TMAs) containing normal terminal duct lobular units (TDLUs) from benign breast biopsies were constructed. Immunostains for IGF1R were performed on sections cut from the TMAs. A total of 312 women had evaluable IGF1R staining in normal TDLUs; 75 subsequently developed breast cancer (cases) and 237 did not (controls). The epithelial cells in the normal TDLUs were scored for both cytoplasmic and membrane staining for IGF1R. Cytoplasmic IGF1R expression was positively associated with subsequent risk of breast cancer (OR = 2.47, 95% CI 1.41–4.33). Women having TDLU epithelial cells showed little or no membrane expression of IGF1R, but those with high levels of cytoplasmic IGF1R were at the highest breast cancer risk and were 15 times more likely to develop subsequent breast cancer when compared with women who had little or no membrane or cytoplasmic IGF1R expression in their TDLU epithelial cells (OR = 15.9, 95% CI 3.6–69.8). In this study, it was demonstrated that IGF1R expression patterns in epithelial cells of normal TDLUs in benign breast biopsies were associated with an increased risk of subsequent breast cancer. Further studies to confirm these findings are necessary.
Literatur
1.
Zurück zum Zitat Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505–518PubMedCrossRef Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505–518PubMedCrossRef
2.
Zurück zum Zitat Rubin R, Baserga R (1995) Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73(3):311–331PubMed Rubin R, Baserga R (1995) Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73(3):311–331PubMed
3.
Zurück zum Zitat Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMedCrossRef Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMedCrossRef
4.
Zurück zum Zitat Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 13(2):273–278PubMedCrossRef Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 13(2):273–278PubMedCrossRef
5.
Zurück zum Zitat Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, Palli D, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larranaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13(2):593–605PubMedCrossRef Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, Palli D, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larranaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13(2):593–605PubMedCrossRef
6.
Zurück zum Zitat Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13(2):583–592PubMedCrossRef Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13(2):583–592PubMedCrossRef
7.
Zurück zum Zitat Schernhammer ES, Holly JM, Pollak MN, Hankinson SE (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14(3):699–704PubMedCrossRef Schernhammer ES, Holly JM, Pollak MN, Hankinson SE (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14(3):699–704PubMedCrossRef
8.
Zurück zum Zitat Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53(16):3736–3740PubMed Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53(16):3736–3740PubMed
9.
Zurück zum Zitat Arteaga CL, Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49(22):6237–6241PubMed Arteaga CL, Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49(22):6237–6241PubMed
10.
Zurück zum Zitat Brunner N, Spang-Thomsen M, Cullen K (1996) The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 39(1):87–92PubMedCrossRef Brunner N, Spang-Thomsen M, Cullen K (1996) The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 39(1):87–92PubMedCrossRef
11.
Zurück zum Zitat Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA (2007) Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 26(11):1636–1644PubMedCrossRef Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA (2007) Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 26(11):1636–1644PubMedCrossRef
12.
Zurück zum Zitat Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65(9):3781–3787PubMedCrossRef Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 65(9):3781–3787PubMedCrossRef
13.
Zurück zum Zitat Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM (2000) Cooperative interaction between mutant p53 and des(1–3)IGF-I accelerates mammary tumorigenesis. Oncogene 19(7):889–898PubMedCrossRef Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM (2000) Cooperative interaction between mutant p53 and des(1–3)IGF-I accelerates mammary tumorigenesis. Oncogene 19(7):889–898PubMedCrossRef
14.
Zurück zum Zitat Kleinberg DL, Wood TL, Furth PA, Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30(1):51–74PubMedCrossRef Kleinberg DL, Wood TL, Furth PA, Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30(1):51–74PubMedCrossRef
15.
Zurück zum Zitat Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18 Pt 2):5549s–5555sPubMedCrossRef Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18 Pt 2):5549s–5555sPubMedCrossRef
16.
Zurück zum Zitat Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS (2006) Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 5(1):114–120PubMedCrossRef Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS (2006) Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 5(1):114–120PubMedCrossRef
17.
Zurück zum Zitat Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63(24):8912–8921PubMed Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63(24):8912–8921PubMed
18.
Zurück zum Zitat Colditz GA, Hankinson SE (2005) The Nurses’ Health Study: lifestyle and health among women. Nat Rev Cancer 5(5):388–396PubMedCrossRef Colditz GA, Hankinson SE (2005) The Nurses’ Health Study: lifestyle and health among women. Nat Rev Cancer 5(5):388–396PubMedCrossRef
19.
Zurück zum Zitat Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2006) The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses’ Health Study. Cancer 107(6):1240–1247PubMedCrossRef Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2006) The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses’ Health Study. Cancer 107(6):1240–1247PubMedCrossRef
20.
Zurück zum Zitat Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11):2698–2708PubMedCrossRef Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11):2698–2708PubMedCrossRef
21.
Zurück zum Zitat Collins LC, Wang Y, Connolly JL, Baer HJ, Hu R, Schnitt SJ, Colditz GA, Tamimi RM (2009) Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue. Appl Immunohistochem Mol Morphol. 17(5):438–441 PMCID: PMC2783452PubMedCrossRef Collins LC, Wang Y, Connolly JL, Baer HJ, Hu R, Schnitt SJ, Colditz GA, Tamimi RM (2009) Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue. Appl Immunohistochem Mol Morphol. 17(5):438–441 PMCID: PMC2783452PubMedCrossRef
22.
Zurück zum Zitat Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A (1993) Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 268(2):1087–1094PubMed Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A (1993) Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 268(2):1087–1094PubMed
23.
Zurück zum Zitat Soos MA, Nave BT, Siddle K (1993) Immunological studies of type I IGF receptors and insulin receptors: characterisation of hybrid and atypical receptor subtypes. Adv Exp Med Biol 343:145–157PubMed Soos MA, Nave BT, Siddle K (1993) Immunological studies of type I IGF receptors and insulin receptors: characterisation of hybrid and atypical receptor subtypes. Adv Exp Med Biol 343:145–157PubMed
24.
Zurück zum Zitat Takahashi MH, Thomas GA, Williams ED (1995) Evidence for mutual interdependence of epithelium and stromal lymphoid cells in a subset of papillary carcinomas. Br J Cancer 72(4):813–817PubMedCrossRef Takahashi MH, Thomas GA, Williams ED (1995) Evidence for mutual interdependence of epithelium and stromal lymphoid cells in a subset of papillary carcinomas. Br J Cancer 72(4):813–817PubMedCrossRef
25.
Zurück zum Zitat Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed
26.
Zurück zum Zitat Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183(4):412–417PubMedCrossRef Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A (1997) The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183(4):412–417PubMedCrossRef
27.
Zurück zum Zitat Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7):893–901PubMedCrossRef Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7):893–901PubMedCrossRef
28.
Zurück zum Zitat Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, Larsson O (2010) SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3 (108):ra10. doi:3/108/ra10 [pii]10.1126/scisignal.2000628 Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, Larsson O (2010) SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 3 (108):ra10. doi:3/108/ra10 [pii]10.​1126/​scisignal.​2000628
29.
Zurück zum Zitat Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70(16):6412–6419 PMCID: PMC2981028PubMedCrossRef Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM (2010) Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 70(16):6412–6419 PMCID: PMC2981028PubMedCrossRef
30.
Zurück zum Zitat Tushir JS, Clancy J, Warren A, Wrobel C, Brugge JS, D’Souza-Schorey C (2010) Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts morphogenesis. Mol Biol Cell 21(13):2355–2366 PMCID: PMC2893997PubMedCrossRef Tushir JS, Clancy J, Warren A, Wrobel C, Brugge JS, D’Souza-Schorey C (2010) Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts morphogenesis. Mol Biol Cell 21(13):2355–2366 PMCID: PMC2893997PubMedCrossRef
31.
Zurück zum Zitat Sorkin A, Goh LK (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315(4):683–696PubMedCrossRef Sorkin A, Goh LK (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315(4):683–696PubMedCrossRef
32.
Zurück zum Zitat Romanelli RJ, LeBeau AP, Fulmer CG, Lazzarino DA, Hochberg A, Wood TL (2007) Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem 282(31):22513–22524PubMedCrossRef Romanelli RJ, LeBeau AP, Fulmer CG, Lazzarino DA, Hochberg A, Wood TL (2007) Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem 282(31):22513–22524PubMedCrossRef
33.
Zurück zum Zitat Sehat B, Andersson S, Girnita L, Larsson O (2008) Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68(14):5669–5677PubMedCrossRef Sehat B, Andersson S, Girnita L, Larsson O (2008) Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68(14):5669–5677PubMedCrossRef
34.
Zurück zum Zitat Kermorgant S, Zicha D, Parker PJ (2004) PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 23(19):3721–3734PubMedCrossRef Kermorgant S, Zicha D, Parker PJ (2004) PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 23(19):3721–3734PubMedCrossRef
35.
Zurück zum Zitat Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP (2008) Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 15(2):209–219PubMedCrossRef Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP (2008) Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 15(2):209–219PubMedCrossRef
36.
Zurück zum Zitat Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC (2008) The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 14(12):3814–3822PubMedCrossRef Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC (2008) The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 14(12):3814–3822PubMedCrossRef
37.
Zurück zum Zitat Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials–early lessons. J Mammary Gland Biol Neoplasia 13(4):471–483 PMCID: PMC2728362PubMedCrossRef Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials–early lessons. J Mammary Gland Biol Neoplasia 13(4):471–483 PMCID: PMC2728362PubMedCrossRef
Metadaten
Titel
Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer
verfasst von
Rulla M. Tamimi
Graham A. Colditz
Yihong Wang
Laura C. Collins
Rong Hu
Bernard Rosner
Hanna Y. Irie
James L. Connolly
Stuart J. Schnitt
Publikationsdatum
01.07.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1313-1

Weitere Artikel der Ausgabe 1/2011

Breast Cancer Research and Treatment 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.